3 Dividend Aristocrats With the Most Room to Keep Raising Their Dividends

Roper Technologies, Brown & Brown and Nordson have dividend payout ratios of roughly 14%, 22% and 38% of trailing diluted EPS, respectively, supporting potential for further increases. Their latest quarterly raises were about 10%, 9% and 14.6%; Nordson also reported 12% organic sales growth and backlog up 35% year over year, while Brown & Brown cited just 1.2% organic growth last quarter and guided to a 2%-4% fourth-quarter decline in Specialty Distribution. The article highlights dividend capacity but notes risks from Roper’s higher interest expense, Brown & Brown’s slower organic growth and Nordson’s exposure to cyclical semiconductor spending.

Analysis

The investable distinction is capital-allocation flexibility, not near-term income: these low yields make the stocks equity-compounding stories, so dividend capacity alone is unlikely to drive a durable rerating. Aristocrat status may already be reflected in ownership; a higher dividend growth rate can coexist with flat total returns if earnings multiples contract.

ROP has the clearest defensive profile if recurring software revenue holds, but its cash cushion competes with debt-funded repurchases and acquisition spending. Higher interest expense makes incremental buybacks less accretive if borrowing costs stay elevated; monitor net leverage and interest burden, not just payout ratio. BRO’s key swing factor is organic growth: weaker property pricing can pressure commissions before acquisition synergies arrive, making the low multiple vulnerable to estimate cuts. NDSN offers more cyclical upside, but recent conversion and growth should not be extrapolated through a semiconductor-capex downturn; reported EPS is also distorted by a noncash investment loss, so assess normalized earnings and cash conversion separately.

Over 1–3 months, guidance revisions on BRO organic growth and NDSN electronics demand matter more than another routine dividend increase. Over 6–18 months, ROP’s debt trajectory and BRO’s delivery of integration synergies determine whether retained cash compounds or merely offsets leverage. The contrarian point: “room to raise” is not protection from multiple compression or a cyclical earnings reset. No clear dividend-driven trade; favor selective entry after operating evidence rather than buying the Aristocrat label.

Key Decisions for Investors

• Do not treat the trio as income substitutes: yields are modest, and the thesis is earnings and dividend growth. Avoid adding solely on the payout-ratio screen.
• ROP: put on a watchlist for pullbacks as a quality-compounder candidate; require stable recurring-revenue trends and falling or contained net leverage before adding. Thesis weakens if interest expense rises while buybacks continue to rely on debt.
• BRO: wait for evidence that organic growth stabilizes before positioning for valuation recovery. Track retail/specialty growth and realized Accession synergies; further organic deterioration or delayed synergy delivery would falsify the recovery case.
• NDSN: treat as a cyclical exposure, not a defensive dividend holding. Reassess on semiconductor-capex and backlog signals; sustained order/backlog weakness or cash conversion falling below net income would argue against the recent growth premium.